Psycho Neuroendocrino Immune (PNEI) therapy of cancer beyond melatonin

• Autores: Lissoni, Paolo; Colgiago, Massimo; Rovelli, Franco; Messina, Giusy; Porro, Giorgio; Monzon, Alejandra; Merlini, Desirée; Di Fede, Giuseppe; Cardinali, Daniel Pedro
• Año de publicación: 2021
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Novel Approaches in Cancer Study. 2021. 6(4)
• Materia: MELATONINA; CANNABINOIDES; NEUROINMUNOMODULACION; OXITOCINA; CANCER; CANCER DE MAMA
• Institución: Pontificia Universidad Católica Argentina

Fil: Lissoni, Paolo. Institute of Biological Medicine; Italia
Fil: Colgiago, Massimo. Istituto Nazionale di Ricovero e Cura per Anziani; Italia
Fil: Rovelli, Franco. Instituto de Medicina Biológica; Italia
Fil: Messina, Giusy. Instituto de Medicina Biológica; Italia
Fil: Porro, Giorgio. Instituto de Medicina Biológica; Italia
Fil: Monzon, Alejandra. Institute of Biological Medicine; Italia
Fil: Merlini, Desirée. Institute of Biological Medicine; Italia
Fil: Tassoni, Simonetta; Effatà Institute; Italia
Fil: Di Fede, Giuseppe. Instituto de Medicina Biológica; Italia
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Abstract: The recent advances in psycho-neuroendocrino-immunology (PNEI) have demonstrated the existence of a natural anticancer neuroendocrine system, mainly expressed by the pineal gland, endocannabinoid system, oxytocin, and Ang 1-7. Moreover, cancer progression has appeared to be associated with a progressive decline in the pineal and cannabinoid system functions. A new approach to cancer therapy according to a PNEI strategy could simply consist of the correction of the main cancer-related neuroimmune and neuroendocrine alterations through the exogenous administration of the same human natural anticancer molecules, whose production declines with cancer progression. PNEI therapy of cancer, because of its complete lack of toxicity, could be applied also to patients, who failed to respond to the conventional anticancer treatments. Most data available up to now regard the treatment with the pineal anticancer hormone melatonin (MLT), whose efficacy has been proven to be a dose-dependent phenomenon. Preliminary results with other human antitumor molecules, mainly the pineal indole 5-MTT, cannabinoids, oxytocin and probably in particular Ang 1-7, could further amplify the already interesting results obtained with high-dose MLT alone in untreatable advanced cancer patients.